Q1 EPS Estimate for USANA Health Sciences Boosted by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti Csr lifted their Q1 2025 earnings per share (EPS) estimates for shares of USANA Health Sciences in a report released on Tuesday, December 24th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.84 for the quarter, up from their previous estimate of $0.73. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.74 EPS, Q3 2025 earnings at $0.73 EPS, Q4 2025 earnings at $0.78 EPS, FY2025 earnings at $3.09 EPS and FY2026 earnings at $3.63 EPS.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter in the prior year, the firm posted $0.59 earnings per share.

Several other analysts have also recently commented on USNA. DA Davidson upgraded USANA Health Sciences to a “hold” rating in a research report on Friday, December 20th. StockNews.com raised shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 19th.

USANA Health Sciences Stock Down 0.7 %

USNA opened at $35.69 on Friday. The firm’s fifty day simple moving average is $37.88 and its two-hundred day simple moving average is $40.01. USANA Health Sciences has a 52-week low of $31.44 and a 52-week high of $54.81. The company has a market cap of $680.25 million, a price-to-earnings ratio of 12.61, a PEG ratio of 1.25 and a beta of 0.89.

Institutional Trading of USANA Health Sciences

Large investors have recently made changes to their positions in the company. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences in the 3rd quarter valued at $30,000. KBC Group NV increased its holdings in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. Centiva Capital LP acquired a new stake in USANA Health Sciences in the third quarter valued at $213,000. BOKF NA raised its stake in USANA Health Sciences by 99.4% in the second quarter. BOKF NA now owns 5,526 shares of the company’s stock valued at $250,000 after buying an additional 2,755 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in USANA Health Sciences during the 3rd quarter worth about $250,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of USANA Health Sciences stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.